Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290080 | 1.00 | FUCA1 (0.61) | FUCA1GBA1S1PR5S1PR1POLB | |
| SCHEMBL2198568 | 0.88 | FUCA1 (0.58) | FUCA1GBA1S1PR5S1PR1POLB | |
| SCHEMBL2198578 | 0.88 | FUCA1 (0.58) | FUCA1GBA1S1PR5S1PR1POLB | |
| SCHEMBL2198573 | 0.88 | FUCA1 (0.58) | FUCA1GBA1S1PR5S1PR1POLB | |
| SCHEMBL3121007 | 0.87 | UBE2M (0.60) | FUCA1POLBDRD2DRD4DRD3 | |
| SCHEMBL11332724 | 0.87 | FUCA1 (0.56) | FUCA1GBA1DRD2DRD4KMT2A | |
| SCHEMBL2221237 | 0.87 | UBE2M (0.60) | FUCA1POLBDRD2DRD4DRD3 | |
| SCHEMBL2190406 | 0.87 | FUCA1 (0.56) | FUCA1GBA1S1PR5S1PR1POLB | |
| SCHEMBL2221234 | 0.87 | UBE2M (0.60) | FUCA1POLBDRD2DRD4DRD3 | |
| SCHEMBL11332733 | 0.87 | FUCA1 (0.56) | FUCA1GBA1DRD2DRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | FUCA1 254/4885GBA1 442/4885S1PR5 3614/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | FUCA1 303/4885GBA1 317/4885S1PR5 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.